GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals

@article{Hu2009GSK3IS,
  title={GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals},
  author={S Hu and Aynun N. Begum and Mychica R Jones and Mike S Oh and Sally Ann Frautschy},
  journal={Neurobiology of Disease},
  year={2009},
  volume={33},
  pages={193-206}
}
The dysregulation of glycogen synthase kinase-3 (GSK3) has been implicated in Alzheimer disease (AD) pathogenesis and in Abeta-induced neurotoxicity, leading us to investigate it as a therapeutic target in an intracerebroventricular Abeta infusion model. Infusion of a specific GSK3 inhibitor SB216763 (SB) reduced a downstream target, phospho-glycogen synthase 39%, and increased glycogen levels 44%, suggesting effective inhibition of enzyme activity. Compared to vehicle, Abeta increased GSK3… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…